Searched for: in-biosketch:true
person:saxena03
Impact of phosphodiesterase-5 inhibitor treatment delay on secondary Raynaud's phenomenon outcomes: A retrospective cohort study
Zappi, Isabella; Maas, Derek; Sikora, Michelle; Spindler, Archie; Nohria, Ambika; Desai, Deesha D; Obijiofor, Chinemelum; Richardson, William Mark; Shapiro, Jerry; Femia, Alisa N; Saxena, Amit; Caplan, Avrom S; Mazori, Daniel R; Lo Sicco, Kristen I
PMID: 42190748
ISSN: 1097-6787
CID: 6075538
Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study
Pike, Marilyn; Saxena, Amit; Furie, Richard A; Nash, Peter; Dörner, Thomas; Hobar, Coburn; Pomponi, Samantha; Jou, Ying-Ming; Banerjee, Subhashis; Wegman, Thomas; Merrill, Joan T
OBJECTIVE:Assess the impact of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, on arthritis in patients with systemic lupus erythematosus (SLE) in a post-hoc analysis from the PAISLEY SLE study (NCT03252587). METHODS:PAISLEY SLE was a 48-week, global, double-blind, placebo-controlled, phase II study evaluating deucravacitinib (3 mg two times per day), 6 mg two times per day and 12 mg one time per day in SLE. Patients with ≥6 swollen, tender or active (swollen plus tender) joints and those with any joint involvement at baseline were evaluated from weeks 4 to 48. Arthritis efficacy was assessed by 100% reduction (JC-100) or ≥50% reduction (JC-50) from baseline in joint count using non-responder imputation. ORs were calculated using logistic regression. Proportions of patients demonstrating musculoskeletal involvement, as assessed by British Isles Lupus Assessment Group 2004 (BILAG-2004) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) domain scores, were also evaluated. RESULTS:More patients achieved JC-100 with deucravacitinib versus placebo whether they had ≥1 or ≥6 tender or active joints at baseline. At week 48, JC-100 active joint responses in patients with ≥6 joints involved were deucravacitinib 3 mg two times per day (n=38/63), 60.3%; 6 mg two times per day (n=26/65), 40.0%; 12 mg one time per day (n=28/62), 45.2%; and placebo (n=20/64), 31.3%. At week 48, ORs for JC-100 for swollen, tender or active joints with deucravacitinib 3 mg two times per day versus placebo were 3.4, 2.0 and 3.3, respectively. Comparable responses and ORs were seen with achievement of JC-50 for swollen, tender or active joints at all deucravacitinib doses. More patients receiving deucravacitinib versus placebo had musculoskeletal score improvements by both BILAG-2004 and SLEDAI-2K at week 48. CONCLUSION:Deucravacitinib was associated with improvements in arthritis in patients in the phase II PAISLEY SLE study. Results will be further evaluated in ongoing phase III studies.
PMCID:13723908
PMID: 42957325
ISSN: 2053-8790
CID: 6074800
Association of Disease Activity and Socioeconomic Factors With Physical Activity in Patients With Systemic Lupus Erythematosus
Gold, Heather T; Giunta, Isabella; Kim, Jiyu; Li, Yi; Buyon, Jill P; Izmirly, Peter M; Masson, Mala; Saxena, Amit; Belmont, H Michael; Tseng, Chung-E; Anthopolos, Rebecca
OBJECTIVE:Physical activity can reduce cardiovascular disease and depression risk and improve quality of life in patients with systemic lupus erythematosus (SLE). To facilitate physical activity and achieve health benefits in patients with SLE, it is critical to understand potential barriers to physical activity, including socioeconomic, social, demographic, quality-of-life, or clinical factors. METHODS:We conducted cross-sectional analyses of data from a large, diverse cohort of patients with SLE. All completed the International Physical Activity Questionnaire, recalling the past seven days of vigorous physical activity, moderate activity, or walking. Data included financial insecurity, Everyday Discrimination Scale, education, demographics, lupus-specific disease activity, immunosuppressive medication, Census Block Area Deprivation Index, and patient-reported pain, fatigue, and cognitive function. Multivariable models included logistic regression for dichotomous outcome of "any" moderate/vigorous physical activity and quasi-Poisson model for total combined days of moderate and vigorous activity. RESULTS:Of the 271 participants, 170 (63%) reported any moderate or vigorous activity in the past 7 days (mean = 2.6 days of moderate/vigorous activity). Only 4% reported zero days of physical activity. Logistic regression analysis indicated that active disease was associated with 47% lower odds of engaging in any moderate/vigorous physical activity (P = 0.04) and with a 35% reduction in the mean number of days of moderate to vigorous physical activity (P = 0.04). In contrast, individual- and area-level socioeconomic factors and patient-reported outcomes were not associated with physical activity. CONCLUSION/CONCLUSIONS:Moderate/vigorous physical activity was negatively associated only with disease activity. The current study reinforces the need primarily to control SLE disease activity to promote patients' ability to be physically active, which may improve symptoms.
PMCID:13545506
PMID: 42698225
ISSN: 2578-5745
CID: 6072032
Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation
Gutowski, Emily; Modi, Yasha; Velez, Alfredo Gutierrez; Colcombe, Joseph; Lee, Carol; Dai, Jessica; Carter, Erin; Izmirly, Juliet; Masson, Mala; Cohen, Brooke; Tseng, Chung-E; Saxena, Amit; Belmont, H Michael; Buyon, Jill; Izmirly, Peter
BACKGROUND/UNASSIGNED:Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) management. However, the medication can accumulate within organs and cause toxicity including retinopathy. HCQ is usually discontinued once ocular toxicity is diagnosed, but this is not always sufficient to avoid further damage. Whether retinal injury progresses following HCQ cessation, and which patients are at risk, is of great interest. Prior studies examining progression after HCQ discontinuation are sparse and limited by small sample sizes, and none specifically examine patients with SLE. This study aimed to identify predictors of progression of HCQ-induced retinopathy in SLE patients after medication discontinuation. METHODS/UNASSIGNED:We queried the NYU Lupus Cohort to identify patients with documented HCQ-induced retinopathy who discontinued HCQ and had at least one optical coherence tomography (OCT) follow-up to assess for progression. Demographic information, cumulative HCQ dose, duration of therapy, presence of chronic kidney disease or tamoxifen use, SLE disease activity, and ophthalmologic follow-up intervals were collected. Two ophthalmologists independently reviewed OCT and Humphrey visual field data to confirm retinopathy, grade its severity, and determine progression following drug discontinuation. Statistical analysis was performed using Student's t-test or Wilcoxon rank-sum test for continuous variables and Chi-square or Fisher's exact test for categorical variables. RESULTS/UNASSIGNED:Twenty-one patients with confirmed HCQ retinopathy were included. The mean duration of HCQ therapy preceding diagnosis was 16.2 years and the mean cumulative exposure was 1884 g. Retinal toxicity progressed in 6 patients (28.6%) despite HCQ discontinuation. There appeared to be a trend towards a greater likelihood of progression with more severe retinal toxicity at the time of diagnosis. However, there were no differences between progressors and non-progressors with respect to age at diagnosis, duration or cumulative HCQ exposure, SLE disease activity, tamoxifen use, chronic kidney disease, or guideline-concordant care. CONCLUSIONS/UNASSIGNED:Nearly thirty percent of patients with SLE and HCQ retinopathy progressed despite drug discontinuation. No baseline clinical predictors were associated with progression, though there was a descriptive trend toward greater risk with more severe baseline retinopathy. These data emphasize the importance of continued ocular surveillance for progression of toxicity after discontinuation.
PMCID:13532724
PMID: 42687909
ISSN: 2693-5015
CID: 6071996
Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus
Kahlenberg, J Michelle; Wu, Chun; Vital, Edward; Catlett, Ian M; Crow, Mary K; Sanz, Ignacio; Saxena, Amit; Arriens, Cristina; Hobar, Coburn; Hu, Yanhua
OBJECTIVES/OBJECTIVE:The objective of this paper is to evaluate pharmacodynamic changes in immune-related pathways and serological biomarkers mediated by tyrosine kinase 2 (TYK2) inhibition in patients with systemic lupus erythematosus (SLE) treated with deucravacitinib, an oral, selective TYK2 inhibitor, in the phase 2 PAISLEY SLE trial. METHODS:Whole-blood transcripts, serum proteins, blood cell subsets, and antibody profiles were analysed via chemical ligation-dependent probe amplification assays, immunoassays, and clinical laboratory assays in 363 patients with SLE from the PAISLEY SLE trial and up to 60 commercially sourced healthy volunteer samples matched demographically to patients. Chemical ligation-dependent probe amplification was used to measure 51 immune system-related genes in whole-blood samples collected in 4 independent studies. All analyses were descriptive. RESULTS:At screening, 42 genes and 75 proteins were differentially expressed in patients with SLE vs healthy volunteers. Deucravacitinib treatment resulted in rapid and sustained reductions in interferon (IFN) levels and expression of IFN-responsive genes, IFN-inducible proteins, B-cell pathway markers, and serological biomarkers and increases in complement 3 and 4 expression with similar kinetics vs placebo. Deucravacitinib treatment reduced an IFN signature score in IFN-high and IFN-low subgroups and anti-double-stranded DNA antibody titres in the IFN-high subgroup. CONCLUSIONS:Deucravacitinib demonstrated suppression of IFN and B-cell pathway biomarkers in patients with SLE, supporting its continued evaluation in ongoing phase 3 trials (Program for Evaluation of TYK2 [POETYK] SLE-1 [NCT05617677] and POETYK SLE-2 [NCT05620407]).
PMID: 42660739
ISSN: 1468-2060
CID: 6071833
Correlation of Hydroxychloroquine Whole Blood Levels With Real and Ideal Body Weight Dosing and Development of Retinal Toxicity
Kaiser, Alexis; Colcombe, Joseph; Cobbs, Lucy; Gutowski, Emily; Buyon, Jill; Belmont, Howard; Izmirly, Peter; Saxena, Amit; Modi, Yasha
PURPOSE/UNASSIGNED:To examine the correlation between hydroxychloroquine levels with real body weight and ideal body weight dose and identify patient characteristics at risk for subtherapeutic or supratherapeutic dosing. METHODS/UNASSIGNED:A retrospective chart review of 181 patients with lupus (429 unique hydroxychloroquine whole blood levels) was performed. Hydroxychloroquine levels <100 (indicating medication noncompliance) were excluded (n = 26). Summary statistics, linear regression of hydroxychloroquine level and real body weight/ideal body weight, and odds ratios (ORs) for factors associated with supratherapeutic (>2000 ng/mL) or subtherapeutic (<750 ng/mL) hydroxychloroquine levels were calculated. RESULTS/UNASSIGNED:, respectively. CONCLUSIONS/UNASSIGNED:All dosing schedules show variability in hydroxychloroquine levels. Ideal body weight may correlate more strongly with hydroxychloroquine level than real body weight. Under real body weight-based guidelines, obesity may increase the risk for supratherapeutic hydroxychloroquine levels, and low weight may increase the risk for subtherapeutic levels.
PMCID:13447678
PMID: 42568784
ISSN: 2474-1272
CID: 6070880
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial
Vital, Edward; Wu, Chun; Kahlenberg, J Michelle; Arriens, Cristina; Crow, Mary K; Saxena, Amit; Catlett, Ian M; Hobar, Coburn; Hu, Yanhua
OBJECTIVES/OBJECTIVE:To further understand the mechanism of action of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY SLE trial. METHODS:RNA sequencing (RNA-seq) was performed on samples collected from baseline to week 32 in 363 patients and 56 healthy volunteers. Pharmacodynamics of differentially expressed genes (DEGs) were analysed with linear mixed-effects models using the statistical software package DREAM (differential expression for repeated measures). Single-sample gene set enrichment analysis (ssGSEA) was performed using MSigDB Hallmark and BloodGen3 gene modules. The xCell R package was used to digitally portray the blood cellular heterogeneity landscape. RESULTS:fold change >1; adjusted P < .05). Deucravacitinib modulated up to 2529 genes and SLE-relevant gene sets, including interferon-regulated genes. ssGSEA showed that plasma cell gene sets decreased and myeloid cell gene sets reverted towards normal levels with deucravacitinib; xCell deconvolution revealed significant enrichment of dendritic cell populations with deucravacitinib vs placebo. At baseline, regulatory T-cell gene sets were increased in patients with SLE vs healthy volunteers and further increased with deucravacitinib. There were some variable, dose-dependent increases in naïve and memory B lymphocytes. CONCLUSIONS:Whole blood transcriptome profiling via RNA-seq revealed both expected and novel gene expression changes with deucravacitinib across multiple pathogenic pathways. These data demonstrate successful targeting of pathophysiologic immune mechanisms that should be validated in future studies and support continued evaluation of deucravacitinib in the phase 3 POETYK SLE trials.
PMID: 42115051
ISSN: 1468-2060
CID: 6036492
Patient-reported outcome measures in patients with systemic lupus erythematosus with or without concurrent fibromyalgia
Gold, Heather T; Li, Yi; Anthopolos, Rebecca; Buyon, Jill P; Masson, Mala; Cohen, Brooke; Gutowski, Emily; Saxena, Amit; Belmont, H Michael; Tseng, Chung-E; Corbitt, Kelly; Izmirly, Peter M
ObjectivePatients with systemic lupus erythematosus (SLE) often have concomitant fibromyalgia (FM) or similar symptoms including chronic pain, fatigue, or depression. This study explored whether Patient-Reported Outcomes Measurement Information System (PROMIS) measures provide richer information than 2016 American College of Rheumatology (ACR) FM criteria survey.MethodsPatients with SLE in our convenience cohort were categorized into groups: (1) concurrent FM chronic pain, (2) concurrent non-FM chronic pain, and (3) no chronic pain using 2016 ACR FM Survey. Based on PROs in the FM Survey, we captured comparable PROMIS measures (e.g., depression, fatigue). Associations by pain group were tested using Kruskal-Wallis rank sum test, Shapiro-Wilk normality test, chi-squared test, or Fisher's exact test. Violin plots explored differences across groups.ResultsThe cohort (n = 181) included 31 patients with FM pain, 23 with non-FM chronic pain, and 127 with no chronic pain. Median PROMIS symptom scores (fatigue, sleep disturbance, pain intensity and interference, depression) were highest and cognitive function lowest in the FM group, despite 13% being in remission. There were significant differences on 4 PROMIS measures (cognitive function, fatigue, pain intensity, pain interference) between FM pain and non-FM pain groups (p < .02), the former being worse. There were no significant differences in SLE Disease Activity Index (SLEDAI) score.ConclusionSLE patients with non-FM chronic pain have similar symptoms to FM compared with SLE patients without chronic pain; however, symptoms are not as severe as those meeting FM criteria. PROMIS measures may be used to classify severity more precisely for disease categorization and management.
PMID: 41542933
ISSN: 1477-0962
CID: 5986702
A Guide for Initiating and Managing Chimeric Antigen Receptor T Cell Therapy Clinical Trials in Autoimmune Rheumatic Diseases
Caricchio, Roberto; Bell, Stacie; Bernatsky, Sasha; Dall'Era, Maria; Goddard, David; Kalunian, Kenneth; Kim, Alfred H J; Koumpouras, Fotios; Rubio, Jose; Saxena, Amit; Sheikh, Saira; ,
Chimeric antigen receptor (CAR) T-cell therapy, long transformative in oncology, is now rapidly emerging as a frontier in autoimmune rheumatic diseases, particularly systemic lupus erythematosus (SLE), driven by accumulating evidence of deep B-cell depletion, immune "resetting," and durable drug-free remission in early studies, yet its translation into rheumatology demands mastery of formidable logistical, regulatory, clinical, and ethical complexities that span institutional readiness, multidisciplinary team formation, stringent regulatory compliance, sophisticated operational workflows, comprehensive patient selection and education, meticulous clinical management of both classical toxicities (CRS, ICANS, ICAHT) and autoimmune-specific reactions such as LICATS, robust financial and resource planning, and long-term follow-up extending 15 years or more; successful implementation requires coordinated expertise among rheumatologists, hematologist-oncologists, cellular therapy units, pharmacists, research coordinators, and ICU-capable teams, all embedded within disciplined communication structures, harmonized SOPs, validated PROs, biorepository governance frameworks, and adherence to national and international cellular therapy standards; in parallel, investigators must anticipate bottlenecks such as apheresis access, manufacturing slot scarcity, competing trial enrollment, fluctuating SLE phenotypes, and heterogeneity-driven signal variability, while sustaining patient engagement over years through education, navigation support, and transparent risk/benefit communication; finally, collaboration with industry partners, clinical trial networks, and patient-advocacy organizations is essential for overcoming operational barriers, securing financial sustainability, and ensuring ethical stewardship, so that CAR T-cell clinical trials in autoimmunity can be executed safely, rigorously, and with maximal therapeutic promise for patients.
PMCID:12662744
PMID: 41315006
ISSN: 2578-5745
CID: 5968892
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial
Mackay, Meggan; Wagner, Catriona A; Pinckney, Ashley; Cohen, Jeffrey A; Wallace, Zachary S; Khosroshahi, Arezou; Sparks, Jeffrey A; Lord, Sandra; Saxena, Amit; Caricchio, Roberto; Kim, Alfred Hj; Kamen, Diane L; Koumpouras, Fotios; Askanase, Anca D; Smith, Kenneth; Guthridge, Joel M; Pardo, Gabriel; Mao-Draayer, Yang; Macwana, Susan; McCarthy, Sean; Sherman, Matthew A; Daneshfar Hamrah, Sanaz; Veri, Maria; Walker, Sarah; York, Kate; Tedeschi, Sara K; Wang, Jennifer; Dziubla, Gabrielle E; Castro, Mike; Carroll, Robin; Narpala, Sandeep R; Lin, Bob C; Serebryannyy, Leonid; McDermott, Adrian B; Barry, William T; Goldmuntz, Ellen; McNamara, James; Payne, Aimee S; Bar-Or, Amit; Khanna, Dinesh; James, Judith A
BACKGROUND:Individuals with autoimmune diseases (AD) on immunosuppressants often have suboptimal responses to COVID-19 vaccine. We evaluated the efficacy and safety of additional COVID-19 vaccines in those treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), and B cell-depleting therapy (BCDT), including the impact of withholding MMF/MPA and MTX. METHODS:In this open-label, multicenter, randomized trial, 22 participants taking MMF/MPA, 26 taking MTX, and 93 treated with BCDT who had suboptimal antibody responses to initial COVID-19 vaccines (2 doses of BNT162b2 or mRNA-1273 or 1 dose of AD26.COV2.S) received an additional homologous vaccine. Participants taking MMF/MPA and MTX were randomized (1:1) to continue or withhold treatment around vaccination. The primary outcome was the change in anti-Wuhan-Hu-1 receptor-binding domain (RBD) concentrations at 4 weeks post-additional vaccination. Secondary outcomes included adverse events, COVID-19 , and AD activity through 48 weeks. RESULTS:Additional vaccination increased anti-RBD concentrations in participants taking MMF/MPA and MTX , irrespective of immunosuppressant withholding. BCDT-treated participants also demonstrated increased anti-RBD concentrations, albeit lower than MMF/MPA- and MTX-treated cohorts. COVID-19 occurred in 33% of participants; infections were predominantly mild and included only three non-fatal hospitalizations. Additional vaccination was well-tolerated, with low frequencies of severe disease flares and adverse events. CONCLUSION/CONCLUSIONS:Additional COVID-19 vaccination is effective and safe in individuals with ADs treated with immunosuppressants, regardless of whether MMF/MPA or MTX is withheld. CLINICALTRIALS/RESULTS:gov (NCT05000216; registered August 6, 2021: https://clinicaltrials.gov/ct2/show/NCT05000216).
PMID: 41289027
ISSN: 2379-3708
CID: 5968172